Imatron reports record EBCT sales revenue
Rising sales of its proprietary electron-beam computed tomography scanner sent Imatron’s sales soaring during the second fiscal quarter of 2000. Revenue for the three months ending June 30 was $15.5 million, an increase of 87% over revenue of $8.3
Rising sales of its proprietary electron-beam computed tomography scanner sent Imatrons sales soaring during the second fiscal quarter of 2000. Revenue for the three months ending June 30 was $15.5 million, an increase of 87% over revenue of $8.3 million for the same period a year earlier, the company announced.
Net income for the same three-month period increased $3 million to $1 million, compared to a net loss of $1.9 million for the same period a year ago. Second-quarter revenue increased 37% and net income increased 321% over Imatrons first quarter, end March 31, 2000.
Imatron has shown rising sales of its scanners (which the company calls simply EBT) in the U.S. and abroad. The firm is investing in development of an international sales staff to increase business in Japan, China, Germany, and the Middle East (SCAN, 7/5/00).
The primary use of Imatron scanners has been to detect coronary artery calcium, a technique that has been called into question in a joint statement by the American College of Cardiology and the American Heart Association for the shortage of conclusive studies on its efficacy. Imatrons defenders, in turn, criticized the consensus paper.
So far, the controversy has not dampened Imatrons sales.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
